Allisartan Isoproxil
ApprovedSmall molecule
Allisartan Isoproxil is one of 89 small molecule programs targeting Essential Hypertension. It is currently in Approved.
4
Indications
5
Total Trials
2
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Allisartan Isoproxil
SShenzhen Salubris Pharmaceuticals Co., Ltd.
Approved
Byetta
AstraZenecaPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Essential Hypertension1 trial
Atrial Fibrillation1 trial
Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation
Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT04111419·1,200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Allisartan Isoproxil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details